Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (NQ: CMND ) 1.200 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Apr 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 1.200 Bid (Size) 1.160 (2) Ask (Size) 1.230 (2) Prev. Close 1.200 Today's Range 1.200 - 1.200 52wk Range 0.1000 - 6.800 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Performance YTD -56.83% -56.83% 1 Month +4.35% +4.35% 3 Month -18.92% -18.92% 6 Month +852.38% +852.38% 1 Year +110.53% +110.53% More News Read More Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders April 17, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders April 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine CEO Issues Letter to Shareholders April 09, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More March 30, 2024 Via Benzinga Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression March 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket March 20, 2024 Via Benzinga Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China March 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review March 16, 2024 Via Benzinga Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors March 12, 2024 Via Benzinga Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds February 27, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder February 23, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents February 21, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? February 20, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From SciSparc Ltd Via GlobeNewswire Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.